Potential first-in-class

Discover the landscape of Potential first-in-class in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Potential first-in-class, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib
CompanyDrug

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GlaxoSmithKline Plc (GSK; NYSE: GSK) announced the first global data for risvutatug rezetecan (Ris‑Rez, HS‑20093), its investigational B7‑H3‑targeted antibody‑drug conjugate (ADC), in patients with relapsed extensive‑stage small cell lung cancer…

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery

CompanyDeals

Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy

CompanyDrug

GSK’s Ojjaara Approved by FDA for Anemic Myelofibrosis Patients

CompanyDrug

Japan’s MHLW Reviews GSK’s Momelotinib for Myelofibrosis Treatment

CompanyDrug

MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies

CompanyDrug

BMS Announces Positive Outcomes for BMS-986278 in Progressive Pulmonary Fibrosis Study

CompanyDrug

Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study

CompanyDrug

BMS’ Reblozyl Expands Indication to Include First-Line MDS-Related Anemia Treatment

Show More